Researchers identify best treatment for iron deficiency anemia in children
UT Southwestern Medical Center Jul 01, 2017
Researchers in the Department of Pediatrics at UT Southwestern Medical Center have identified the most effective treatment approach for children diagnosed with iron–deficiency anemia (IDA).
The study, published online in the Journal of the American Medical Association, compared the efficacy of ferrous sulfate versus an iron polysaccharide complex  two of the more common therapies used to increase hemoglobin concentration in infants and young children with IDA. They found that once daily, oral low–dose ferrous sulfate (iron salt) provided a statistically significant increase in hemoglobin concentration compared with the iron polysaccharide complex.
ÂThe rigorous, randomized clinical trial our research team performed was the first to compare two different iron supplements by defining the optimal dose and duration of iron treatment necessary in order to correct the anemia, said Dr. George Buchanan, Professor Emeritus of Pediatrics at UT Southwestern specializing in Pediatric Hematology–Oncology at UT Southwestern and ChildrenÂs Health. ÂOur hope is that these findings will have a substantial impact on standards of care for children with iron–deficiency anemia by offering an evidence–based treatment approach.Â
IDA in infants and young children is most often the result of prolonged breast–feeding without iron supplementation and/or excessive intake of cowÂs milk. Symptoms of IDA in children as well as adults include extreme fatigue, weakness, poor appetite, headache, and dizziness or lightheadedness.
This study, conducted at ChildrenÂs Medical Center in Dallas, was performed over 12 weeks as a randomized clinical trial of 80 male and female patients ages 9 to 48 months who had been previously diagnosed with IDA.
Other implications of this finding include improving treatments for teenagers and adults suffering from IDA as a result of heavy menstrual bleeding and other causes. Further research will explore if a once daily, low–dose ferrous sulfate improves hemoglobin concentration in those patients as well.
The studyÂs research team includes Dr. Jacquelyn Powers, who is now an Assistant Professor of Pediatrics at Baylor College of Medicine and Texas ChildrenÂs Hospital; Dr. Timothy McCavit, who is now a hematology/oncology physician at Cook ChildrenÂs Medical Center; Dr. Song Zhang, Associate Professor of Clinical Sciences at UT Southwestern; Ang Gao, biostatistical consultant in the Department of Clinical Sciences at UT Southwestern; and Leah Adix, senior research coordinator at ChildrenÂs Medical Center.
Go to Original
The study, published online in the Journal of the American Medical Association, compared the efficacy of ferrous sulfate versus an iron polysaccharide complex  two of the more common therapies used to increase hemoglobin concentration in infants and young children with IDA. They found that once daily, oral low–dose ferrous sulfate (iron salt) provided a statistically significant increase in hemoglobin concentration compared with the iron polysaccharide complex.
ÂThe rigorous, randomized clinical trial our research team performed was the first to compare two different iron supplements by defining the optimal dose and duration of iron treatment necessary in order to correct the anemia, said Dr. George Buchanan, Professor Emeritus of Pediatrics at UT Southwestern specializing in Pediatric Hematology–Oncology at UT Southwestern and ChildrenÂs Health. ÂOur hope is that these findings will have a substantial impact on standards of care for children with iron–deficiency anemia by offering an evidence–based treatment approach.Â
IDA in infants and young children is most often the result of prolonged breast–feeding without iron supplementation and/or excessive intake of cowÂs milk. Symptoms of IDA in children as well as adults include extreme fatigue, weakness, poor appetite, headache, and dizziness or lightheadedness.
This study, conducted at ChildrenÂs Medical Center in Dallas, was performed over 12 weeks as a randomized clinical trial of 80 male and female patients ages 9 to 48 months who had been previously diagnosed with IDA.
Other implications of this finding include improving treatments for teenagers and adults suffering from IDA as a result of heavy menstrual bleeding and other causes. Further research will explore if a once daily, low–dose ferrous sulfate improves hemoglobin concentration in those patients as well.
The studyÂs research team includes Dr. Jacquelyn Powers, who is now an Assistant Professor of Pediatrics at Baylor College of Medicine and Texas ChildrenÂs Hospital; Dr. Timothy McCavit, who is now a hematology/oncology physician at Cook ChildrenÂs Medical Center; Dr. Song Zhang, Associate Professor of Clinical Sciences at UT Southwestern; Ang Gao, biostatistical consultant in the Department of Clinical Sciences at UT Southwestern; and Leah Adix, senior research coordinator at ChildrenÂs Medical Center.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries